CSIMarket
 
Bluejay Diagnostics Inc   (BJDX)
 

BJDX, contraction in the corporate behavior throughout the financial fourth quarter of 2022

Bluejay Diagnostics Inc recorded fourth quarter of 2022 operating loss of $-2.453612 millions


Published Mar 21 2023
CSIMarket Team / CSIMarket.com


Surgery_By_NathanGrohmann_(Own_work)_[[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Commons As the October to December 31 2022 reporting season resumes, many corporations have disclosed the earnings. Some of them, are multiple constituents of the Medical Equipment & Supplies sector. As well as, now, BJDX announced operating shortfall of $-2.453612 millions, for the fiscal three months closing Dec 31 2022.

In the recent approaching stage of the company, the stakeholders await for new revenue sources to come as early as possible. They are less interested in the prevailing operational behavior of the Bluejay Diagnostics Inc .


The crucial observation in financial interval closing December 31 2022, next to the deficiency in top-line, is a $-2.386 millions net loss, which has expanded notably from $-1.193 millions, compared to the corresponding period a year before.


Bluejay Diagnostics Inc is expected to report next financial results on May 08, 2023.



Bluejay Diagnostics Inc's Receivables Turnover Ratio

Bluejay Diagnostics Inc's Price to earnings ratio PE



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com